Approach

Summary

Licensing status

Publication and contact information

Disease models

A noninvasive, nonhuman primate model of schizophrenia

Nonhuman primates that receive subanesthetic doses of ketamine could be useful as noninvasive preclinical models to study schizophrenia and evaluate therapeutic candidates. Electroencephalograms in ketamine-treated rhesus monkeys produced neurophysiological measurements comparable to those seen in patients with schizophrenia. Next steps include evaluating this model in preclinical drug testing.

SciBX 6(36); doi:10.1038/scibx.2013.1007
Published online Sept. 19, 2013

Patent filed by the Salk Institute for Biological Studies; available for licensing

Gil-da-Costa, R. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 19, 2013;
doi:10.1073/pnas.1312264110
Contact: Ricardo Gil-da-Costa, Salk Institute for Biological Studies, La Jolla, Calif.
e-mail:

ricardo@salk.edu